| Prev Close | 62.26 |
| Open | 62.63 |
| Day Low/High | 61.60 / 62.69 |
| 52 Wk Low/High | 46.48 / 62.35 |
| Volume | 2.51M |
Astrazeneca PLC Sponsored ADR (AZN)
61.77
0.49
0.79
NYSE
| Exchange | NYSE |
| P/E Ratio | 51.70 |
| Div & Yield | N.A. (N.A) |
What to Watch This Week: Presidential Election, Mylan Earnings
For the week of November 7, all eyes will be on Tuesday's presidential election.
Cramer: Don't Just Stand There Like Bambi; Sell Some
Stocks in the health care sector seem to have no underpinnings whatsoever.
Jim Cramer: AstraZeneca Is Reinventing Itself in Anti-Cancer
Jim Cramer comments on AstraZeneca's recent success in a cancer drug trial.
Chi-Med Not Your Typical 'Binary Biotech' Says CEO
Chi-Med may be pressing ahead with a series of late-stage oncology drug trials, but it is anything but a one-trick pony biotech company.
Cempra Is Ready to Run
Given predictable upcoming catalysts and a large addressable market, this small-cap biotech is a buy.
Big Pharma Has No Rx for Viral Social Media Reactions
Immediate public backlash on social media could end up being a more costly verdict for drugmakers' pricing powers.
Portfolio Manager: Is Pfizer Acquiring Too Quickly?
Pfizer's second acquisition this week could add risk. Some retailers attract portfolio managers.
Pfizer Is Buying a Portion of AstraZeneca's Antibiotics Business
Pfizer is making another acquisition.
4 Stocks to Avoid Amid the Mad 'Search for Yield'
There's a price to pay for low expectations.
Closing Bell: Tinder Boosts Match; Earnings Drive S&P 500 Higher
Another busy day on the earnings calendar kept trading erratic again on Thursday, though the S&P 500 and Nasdaq managed to clinch slight gains by the end of the session.
AstraZeneca Likely to Grind Lower
Barring a strong rally over $31 that has follow-through, we look for AZN to slowly erode.
Bret Jensen Reporting for Duty
Good morning! Bret Jensen here! It's good to be standing in for Doug Kass on Doug's Daily Dairy this Friday, especially on a day when my "Best Idea" Relypsa (RLYP) is likely to soar. After the bell Thursday, the U.S. Food and Drug Administration ess...
2 Small-Cap Biotechs With Big Ambitions
Inovio Pharmaceuticals and Eagle Pharmaceuticals both boast solid pipelines and sound balance sheets.
Relypsa's Still a Bargain Despite 67% Rally
Small biotech has plenty of cash and a very valuable drug.
Relypsa's Still a Bargain Despite 67% Rally
Small biotech has plenty of cash and a very valuable drug.
Tax Clampdown Prompts Pfizer to Scrap Allergan Purchase
CEO Read says the Viagra maker retains the means to pursue 'attractive business development' opportunities as he tears up the six-month-old deal with the maker of Botox.
Pfizer Tops Interbrand's List of Best Biopharmaceutical Brands
Pfizer scored the top spot in Interbrand Health's inaugural ranking of the top ten biopharmaceutical brands.
Revisiting 3 Promising Small Biotechs
They are oversold and lately been on the move.
Don't Throw This Biotech 'Baby' Out With the Bathwater
Drug maker Relypsa is poised for a huge upside, despite the current market sentiment.
Don't Throw This Biotech 'Baby' Out With the Bathwater
Drug maker Relypsa is poised for a huge upside, despite the current market sentiment.
Biotech Stocks Are Beginning to Stir
I am starting to get more confident that the small caps are ready to bounce.
AstraZeneca's Ailment Doesn't Look Treatable
AZN looks vulnerable to further declines. The next downside support area and price target are the $26-$24 area.
2 Speculative Biotech Stocks for 2016
Cempra and Relypsa are two high-risk, high-reward small-caps worth considering.
Asian, European Stocks Surge in the Morning of Fed Interest Rate Day
And four other things you need to know now.
Why Relypsa Is a New 'Best Idea'
It is hard to see the biotech firm not becoming a takeover target.
Greek Parliament Approves Reforms Required by Creditors
And four other things you need to know now.
Chinese Stocks Close Into Bull Market Territory
And four other things you need to know now.
4 Reasons to Buy High Dividend Yield Equities in Europe
As bond yields go negative, dividend yields shine.
Searching for a Bottom in AstraZeneca; $34.50 Is the Critical Level
Our strategy for the stock is to look to buy available weakness in the next few weeks.
